Adefovir Dipivoxil: A New Antiviral Agent for the Treatment of Hepatitis B Virus Infection

Clinical Therapeutics

Volumn 25, Issue 12, 2003, Pages 3084-3099

  Qaqish, Roula B ^a   Mattes, Keri A ^a   Ritchie, David J ^a,b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Adefovir; Adefovir dipivoxil; Antivirals; Hepatitis B

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIVIRUS AGENT; CIDOFOVIR; CIMETIDINE; CREATINE KINASE; CYCLOSPORIN; IBUPROFEN; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PENTAMIDINE; PROBENECID; PROCAINAMIDE; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BIOAVAILABILITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; COUGHING; DATA ANALYSIS; DATA BASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; DUCK; FANCONI RENOTUBULAR SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HERPES VIRUS; HUMAN; HYPERSENSITIVITY; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER METABOLISM; MEDLINE; NEPHROTOXICITY; NONHUMAN; PHARYNGITIS; REVIEW; SINUSITIS; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; VIROLOGY; VIRUS INFECTION; VIRUS ISOLATION; WILD TYPE;

EID: 0347933025     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90093-2     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Hepatitis B Fact Sheet. Available at: www.cdc.gov/hepatitis. Accessed February 12, 2003.
2. World Health Organization. Hepatitis B. Fact Sheets. Available at: www.who.int/ inf-fs/en/fact204.html. Accessed February 12, 2003.
3. Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J. 2001;77: 498-505.
4. Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol. 2002; 17(Suppl):S125-S145.
5. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001:1721-1737.
6. Rivkina A, Rybalov S. Chronic hepatitis B: Current and future treatment options. Pharmacotherapy. 2002;22:721-737.
7. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-323.
8. FDA Advisory Committee Briefing Document: Adefovir dipivoxil for the treatment of chronic hepatitis B. NDA 21-449 Gilead Sciences, Foster City, Calif. July 2002. Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3885B1_01_Gilead.pdf. Accessed February 12, 2003.
9. Malliard ME, Golan JL. Suppressing hepatitis B without resistance - so far, so good. N Engl J Med. 2003;348:848-850.
10. Liaw YF, Leung NW, Chang TT, et al, for the Asia Hepatitis Lamuvidine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172-180.
11. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology. 2001;33:1527-1532.
12. Hepsera [package insert]. Foster City, Calif: Gilead Sciences, Inc; 2002.
13. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B [published correction in N Engl J Med. 2003;348:1192], N Engl J Med. 2003;348:800-807.
15. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
16. Xiong S, Yan H, Westland CE, et al. Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. In: Program and abstracts of the 38th Meeting of the European Association for the Study of the Liver; March 28-April 1, 2003; Istanbul, Turkey. Abstract 4543.
17. Kearney B, Knight W, Currie G, et al. Adefovir dipivoxil pharmacokinetics in subjects with chronic hepatitis B and in healthy subjects. In: Program and abstracts of the 37th Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain. Poster 306.
18. Cundy KC, Barditch-Crovo P, Walker RE. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type I-infected patients. Anrimicrob Agents Chemother. 1995;39:2401-2405.
19. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36:127-143.
20. Kearney B, Knight W, Currie G, et al. Drug-drug interaction study between adefovir dipivoxil and lamivudine, paracetamol, ibuprofen and trimethoprim/sulfamethoxazole. In: Program and abstracts of the 37th Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain. Poster 307.
21. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. 1999;29:1863-1869.
22. Neumann AU, Havlin Y, Tal R, et al. Long-term HBV kinetics classification during treatment with adefovir dipivoxil. J Hepatol. 2002;36(Suppl 1):121. Abstract 849.
23. Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 1993;21:141-153.
24. Nicoll AJ, Colledge DL, Toole JJ, et al. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother. 1998;42:3130-3135.
25. Gangemi JD, Cozens RM, De Clercq E, et al. 9-(2-phosphonylmethoxyethyl) adenine in the treatment of murine acquired immunodeficiency diseases and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother. 1989;33:1864-1868.
26. De Castro LM, Kern ER, De Clercq E, et al. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 1991;16:101-114.
27. Gilson RJ, Chopra KB, Newell AM, et al. A placebo-controlled Phase I/II study of ade-fovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatol. 1999;6:387-395.
28. Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg and se-roconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled Phase II studies. Hepatology. 1998;28:317A. Abstract 620.
29. Heathcote E, Jeffers L, Perrillo R, et al. Serum HBV DNA suppression and serocon-version following long-term adefovir dipivoxil therapy in chronic HBV patients. Hepatology. 2001;34:316A. Abstract 575.
30. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivu-dine-resistant hepatitis B mutants. Hepatology. 2000;32:129-134.
31. Schiff E, Neuhaus P, Tillmann H, et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine-resistant HBV in patients post liver transplantation. Hepatology. 2001;34:446A. Abstract 1098.
32. Schiff E, Neuhaus P, Tillmann H, et al. Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. J Hepatol. 2002;36(Suppl 1):32. Abstract 650.
33. Schiff E, Lai C, Neuhaus P, et al. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre-and post-liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV). Hepatology. 2002;36:371A. Abstract 831.
34. Peters M, Hann HW, Martin P et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) repli-cation: 16 Week interim analysis. J Hepatol. 2002;36(Suppl l):6-7. Abstract 646.
35. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combina-tion with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 Week preliminary analysis. Hepatology. 2002;36:374A. Abstract 845.
36. Perrillo R, Schiff E, Hann HL, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis patients with YMDD variant HBV and reduced re-sponse to lamivudine -preliminary 24 week results. Hepatology. 2001;34:349A. Abstract 708.
37. Mutimer D, Hann HW, Buti M, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant and reduced response to lamivudine-one year results. Antiviral Ther. 2002;7:L90. Abstract 16.
38. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet. 2001;358:718-723.